Glaukos (GKOS) began trading on the NYSE on 25 June 2015

Glaukos (NYSE:GKOS) is developing surgical devices for treating glaucoma. It priced 6 million shares at an above-range 18. The stock popped 73% to 31.22 in its debut Thursday. It fell 10% Friday.

• The ophthalmic medical technology firm focuses on treatments for glaucoma, a group of disorders that is characterized by elevated intraocular pressure (IOP). This eventually damages the optic nerve which leads to vision loss and blindness. The specific category that the company operates in is called Micro-Invasive Glaucoma Surgery (MIGS). Its sole product is the iStent, the only FDA-approved MIGS device to date. The hollow micro-scale device is implanted in the eye through a small incision in the cornea. It reduces IOP by allowing the drainage of fluid, called aqueous humor. The company has sold over 70,000 iStents to date.   

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye's anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies, including three pipeline products, namely, the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Address

26061 Merit Cir Ste 103
LAGUNA HILLS, CA 92653-7010
United States 

Website

http://www.glaukos.com/